Evidence map›Paper›PMID 36608071›Full record

SynthesisAmerican journal of therapeutics

Residual Disease Threshold After Primary Surgical Treatment for Advanced Epithelial Ovarian Cancer, Part 1: A Systematic Review and Network Meta-Analysis.

Andrew Bryant, Eugenie Johnson, Michael Grayling, Shaun Hiu, Ahmed Elattar, Ketankumar Gajjar, Dawn Craig, Luke Vale, Raj Naik

Open access · hybridAbstract readSystematic ReviewNetwork Meta-Analysis
In one paragraph

Synthesis in American journal of therapeutics. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 2 pooled it
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 2 syntheses or guidelines pooled it, 17 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Observational
  11. Review
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Andrew BryantPopulation Health Sciences Institute, Newcastle University, Newcastle upon Tyne, United Kingdom.
Eugenie JohnsonPopulation Health Sciences Institute, Newcastle University, Newcastle upon Tyne, United Kingdom.
Michael GraylingPopulation Health Sciences Institute, Newcastle University, Newcastle upon Tyne, United Kingdom.
Shaun HiuPopulation Health Sciences Institute, Newcastle University, Newcastle upon Tyne, United Kingdom.
Ahmed ElattarPan-Birmingham Gynaecological Oncology Cancer Centre, Birmingham, United Kingdom.
Ketankumar GajjarNottingham City hospital, Obstetrics and Gynaecology, Nottingham, United Kingdom; and.
Dawn CraigPopulation Health Sciences Institute, Newcastle University, Newcastle upon Tyne, United Kingdom.
Luke ValePopulation Health Sciences Institute, Newcastle University, Newcastle upon Tyne, United Kingdom.
Raj NaikNorthern Gynaecological Oncology Centre, Gateshead, United Kingdom.
Newcastle University · GBGateshead Health NHS Foundation Trust · GBNottingham City Hospital · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWe present a systematic review and network meta-analysis (NMA) that is the precursor underpinning the Bayesian analyses that adjust for publication bias, presented in the same edition in AJT. The review assesses optimal cytoreduction for women undergoing primary advanced epithelial ovarian cancer (EOC) surgery. AREAS OF UNCERTAINTY: To assess the impact of residual disease (RD) after primary debulking surgery in women with advanced EOC. This review explores the impact of leaving varying levels of primary debulking surgery. DATA SOURCES: We conducted a systematic review and random-effects NMA for overall survival (OS) to incorporate direct and indirect estimates of RD thresholds, including concurrent comparative, retrospective studies of ≥100 adult women (18+ years) with surgically staged advanced EOC (FIGO stage III/IV) who had confirmed histological diagnoses of ovarian cancer. Pairwise meta-analyses of all directly compared RD thresholds was previously performed before conducting this NMA, and the statistical heterogeneity of studies within each comparison was evaluated using recommended methods. THERAPEUTIC ADVANCES: Twenty-five studies (n = 20,927) were included. Analyses demonstrated the prognostic importance of complete cytoreduction to no macroscopic residual disease (NMRD), with a hazard ratio for OS of 2.0 (95% confidence interval, 1.8-2.2) for <1 cm RD threshold versus NMRD. NMRD was associated with prolonged survival across all RD thresholds. Leaving NMRD was predicted to provide longest survival (probability of being best = 99%). The results were robust to sensitivity analysis including only those studies that adjusted for extent of disease at primary surgery (hazard ratio 2.3, 95% confidence interval, 1.9-2.6). The overall certainty of evidence was moderate and statistical adjustment of effect estimates in included studies minimized bias.

conclusionsThe results confirm a strong association between complete cytoreduction to NMRD and improved OS. The NMA approach forms part of the methods guidance underpinning policy making in many jurisdictions. Our analyses present an extension to the previous work in this area.

Indexed as

Ovarian NeoplasmsAdultBayes TheoremCarcinoma, Ovarian EpithelialFemaleHumansNeoplasm, ResidualNeoplasm StagingRetrospective Studies

Identifiers

PMID36608071
PMCPMC9812425
OpenAlexW4313597900

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.